David Ludvigson - 04 Jun 2021 Form 3 Insider Report for Boston Therapeutics, Inc.

Role
CEO and President, Director
Signature
/s/ David Ludvigson
Issuer symbol
N/A
Transactions as of
04 Jun 2021
Net transactions value
$0
Form type
3
Filing time
29 Jun 2021, 20:46:27 UTC
Next filing
16 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NNMX Common Stock, $0.0001 par value per share 0 04 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NNMX Series C Preferred Stock 04 Jun 2021 Common Stock, $0.0001 par value per share 58,316,292 Direct F1
holding NNMX Warrants 04 Jun 2021 Common Stock, $0.0001 par value per share 6,503,659 $0.003400 Direct F2
holding NNMX Restricted Stock Units 04 Jun 2021 Common Stock, $0.0001 par value per share 181,809,374 $0.000000 Direct F3
holding NNMX Incentive Stock Options 04 Jun 2021 Common Stock, $0.0001 par value per share 7,218,039 $0.000300 Direct F4
holding NNMX Incentive Stock Options 04 Jun 2021 Common Stock, $0.0001 par value per share 96,742,608 $0.001400 Direct F4
holding NNMX Incentive Stock Options 04 Jun 2021 Common Stock, $0.0001 par value per share 14,916,033 $0.001400 Direct F4
holding NNMX Incentive Stock Options 04 Jun 2021 Common Stock, $0.0001 par value per share 14,730,691 $0.001400 Direct F4
holding NNMX Incentive Stock Options 04 Jun 2021 Common Stock, $0.0001 par value per share 22,096,037 $0.001700 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series C Preferred Stock has a stated value of $1.00 per share and is convertible into shares of common stock at a conversation rate of 6,066.044596 shares of common stock for each share of Series C Preferred Stock. The shares of Series C Preferred Stock are automatically converted upon the filing of an amendment to the Company's certificate of incorporation implementing a reverse stock split.
F2 The shares underlying the warrants and the RSU may not be exercised until the implementation of a reverse stock split.
F3 RSUs vesting over 2 years
F4 Previously issued ISO stock options vested and unvested